Switzerland’s Actelion Pharmaceuticals Ltd. may be only 16 years old, but it faces a very grown-up problem: the patent expiry of its blockbuster pulmonary arterial hypertension (PAH) drug, Tracleer (bosentan), which accounts for almost 90% of sales.
The challenge isn’t unusual – most Big Pharma and many mid-caps have lost or soon face losing billions to generics....